Anest. intenziv. Med. 2006;17(3):176-180

Surfactant - use in adult patientsIntensive Care Medicine - Comprehensive Report

D. Romportl, A. Hodek, M. Krečmerová, M. Pelichovská, K. Cvachovec
Anesteziologicko-resuscitační klinika 2. LF UK a Fakultní nemocnice v Motole, Praha

Surfactant is a complex surface-active substance, consisting of lipids and proteins, which lines the surface of terminal bronchioles and alveoli of mammalian lungs. It is responsible for maintaining essential biophysical and immunological functions of the lungs. Surfactant impairment is common in many pathological situations, leading to deterioration of pulmonary function. These facts have been known for about 50 years and since then we have been trying to develop effective treatment based on a natural or synthetic surfactant. In clinical practice, the use of surfactant has been well established only in newborns. In adults, the greatest experience with surfactant treatment has been gained in patients with acute respiratory distress syndrome (ARDS), the results however, being controversial. Recently new, narrower indications for surfactant use have emerged, bringing the first promising results.

Keywords: surfactant; ARDS

Published: June 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Romportl D, Hodek A, Krečmerová M, Pelichovská M, Cvachovec K. Surfactant - use in adult patients. Anest. intenziv. Med. 2006;17(3):176-180.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Jobe, A. H. Pulmonary surfactant therapy. N. Engl. J. Med., 1993, 328, p. 861-868. Go to original source... Go to PubMed...
    2. Soll, R. F. Clinical trials of surfactant therapy in the newborn. In Robertson, B., Taeusch, H. W. (edit.) Surfactant Therapy for Lung Disease. New York : Marcel Dekker 1995, p. 407-442.
    3. Gunther, A. et al. Surfactant alteration and replacement in acute respiratory distress syndrome. Review: available online http://respiratory-research.com/content/2/6/353.
    4. Whitsett, J. A. Hydrophobic Surfactant protein in lung function and disease. N. Engl. J. Med., 2002, 347, p. 2141-2148. Go to original source... Go to PubMed...
    5. Petty, T. L. Abnormalities in lung elastic properties and surfactant function in adult respiratory distress syndrome. Chest, 1979, 75, p. 571-574. Go to original source... Go to PubMed...
    6. Anzueto, A. et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N. Engl. J. Med., 1996, 334, p. 1417-1421. Go to original source... Go to PubMed...
    7. Gregory, T. J. et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med., 1997, 155, p. 1309-1315. Go to original source... Go to PubMed...
    8. Willson, D. F. et al. Instilation of calf lung surfactant extract is beneficial in pediatric acute hypoxemic respiratory failure. Members of the Mid-Atlantic Pediatric Critical Care Network. Crit. Care Med., 1999, 27, p. 188-195. Go to original source... Go to PubMed...
    9. Wiswell, T. E. et al. Bronchopulmonary segmental lavage with Surfaxin (KL4-Surfactant) for acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med., 1999, 160, p. 1188-1195. Go to original source... Go to PubMed...
    10. The Acute Respiratory Distress Syndrome Network: Ventilation with Lower Tidal Volumes as Compared with Traditional Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome. N. Engl. J. Med., 342, 2000, p. 1301-1308. Go to original source... Go to PubMed...
    11. Veldhuizen, R. A. W. et al. Alteration in pulmonary surfactant composition and activity after experimental lung transplantation. Am. Rev. Respir. Dis., 1993, 148, p. 208-215. Go to original source... Go to PubMed...
    12. Hohlfeld, J. M. et al. Pulmonary surfactant activity is impaired in lung transplant recipients. Am. J. Respir. Crit. Care Med., 1998, 158, p. 706-712. Go to original source... Go to PubMed...
    13. Struber, M. et al. Surfactant replacement in reperfusion injury after clinical lung transplantation. Intensive Care Med., 1999, 25, p. 862-864. Go to original source... Go to PubMed...
    14. Luchetti, M. et al. Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Pediatr. Crit. Care Med., 2002, 3, p. 261-268. Go to original source... Go to PubMed...
    15. Creuwels, L. A., van Golde, L. M., Haagsman, H. P. The pulmonary surfactant system: biochemical and clinical aspects. Lung, 1997, 175, p. 1-39. Go to original source... Go to PubMed...
    16. Griese, M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur. Respir. J., 1999, 13, p. 1455-1476. Go to original source... Go to PubMed...
    17. Spragg, R. C. et al. Acute Effects of a single dose of porcine surfactant on patiens with adult respiratory distress syndrome. Chest, 1994, 105, p. 195-202. Go to original source... Go to PubMed...
    18. Walmrath, D. et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur. Respir. J., 2002, 19, p. 805-810. Go to original source... Go to PubMed...
    19. Spragg, R. C. et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N. Engl. J. Med., 2004, 351, p. 884-892. Go to original source... Go to PubMed...
    20. Ainsworth, S. B. Pathophysiology of Neonatal Respiratory Distress Syndrome: Implications of Early Treatment Strategie. Treat. Respir. Med., 2005, 4, p. 423-437. Go to original source... Go to PubMed...

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.